Real-life Diagnostic and Therapeutic Approach to CLL: A New Proposal from an Expert Panel in Tuscany Region

Monica Bocchia, Alberto Bosi, Enrico Capochiani, Stefania Ciolli, Romano Danesi, Sara Galimberti, Alessandro Gozzetti, Sabrina Moretti, Ubaldo Occhini, Mario Petrini

DOI: https://doi.org/10.7175/fe.v21i1.1452

Abstract

BACKGROUND: In the last years genomic and somatic alterations have shown to play a pivotal role in the pathogenesis of chronic lymphocytic leukemia (CLL) and new prognostic factors have been identified accordingly.

AIM: To describe a real-life diagnostic and therapeutic approach to CLL that takes into account the role of genomic and somatic prognostic factors in the risk stratification of developing progressive disease, and treatment decision.

METHODS: This new proposal has been developed and validated by ten key opinion leaders from Tuscany Region during two Expert Meetings. The approach suggested comes from their experience in daily clinical practice and is supported by guidelines recommendations, clinical trials results, and drugs prescribing conditions in Italy.

RESULTS: Beside TP53 deletion or mutated status, the Expert Panel highlighted the importance of the IGHV mutation status characterization, since the diagnosis, in order to identify patients who will have a more aggressive progression. Furthermore, just before starting treatment, to obtain useful prognostic information and indication in the selection of the therapy, they recommend cytogenetic analysis for the detection of del(11q), trisomy 12, del(13q), del(17p), conventional karyotyping of stimulated CLL cells, TP53 sequencing, and molecular genetic analysis to detect IGHV mutation status.

CONCLUSIONS: The Expert Panel recognized the limitations associated with traditional staging systems in identifying patients who will have a more aggressive disease course and predicting response to treatment and suggested a real-life diagnostic and therapeutic approach to CLL to update the current patient management in light of recent advances that have improved understanding of CLL.

Keywords

Chronic lymphocytic leukemia; Prognostic factors; TP53 deletion; IGHV mutation status

Full Text

HTML PDF

References

  • Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. In: WHO Classification of Tumours. 4th Edition, Volume 2. IARC: Lyon, 2016
  • SEER Cancer Stat Facts: Chronic Lymphocytic Leukemia. National Cancer Institute. Bethesda, MD. Available at https://seer.cancer.gov/statfacts/html/clyl.html (Last accessed November 2020)
  • Gruber M, Wu CJ. Evolving understanding of the CLL genome. Semin Hematol 2014; 51: 177-87; https://doi.org/10.1053/j.seminhematol.2014.05.004
  • Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46: 219-34; https://doi.org/10.1182/blood.V46.2.219.219
  • Rai KR. A critical analysis of staging in CLL. In: Gale RP, Rai KR, eds. Chronic Lymphocytic Leukemia: Recent Progress and Future Directions. New York, NY: Alan R. Liss; 1987: 253-64
  • Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198–206
  • Baliakas P, Mattsson M, Stamatopoulos K, et al. Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed? J Intern Med 2016; 279: 347-57; https://doi.org/10.1111/joim.12455
  • Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-7; https://doi.org/10.1182/blood.V94.6.1840
  • Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-54; https://doi.org/10.1182/blood.V94.6.1848
  • Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018; 131: 2745-60; https://doi.org/10.1182/blood-2017-09-806398
  • Wierda WG, Byrd JC, Abramson JS, et al. NCCN Clinical Practice Guidelines in Oncology. Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. Version 2.2020, October 8, 2019 (Last Accessed October 2019)
  • International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol 2016; 17: 779-90; https://doi.org/10.1016/S1470-2045(16)30029-8
  • Delgado J, Doubek M, Baumann T, et al. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. Am J Hematol 2017; 92: 375-80; https://doi.org/10.1002/ajh.24660
  • Thompson PA, Tam CS, O’Brien SM, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 2016; 127: 303-9; https://doi.org/10.1182/blood-2015-09-667675
  • Burger J, Barr P, Robak T, et al. Ibrutinib For First-Line Treatment Of Older Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Cll/Sll): A 4-Year Experience From The Resonate-2 Study. EHA Learning Center 2018; 214817. Abstract: PF343
  • Burger JA, Tedeschi A, Barr PM, et al.; RESONATE-2 Investigators. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med 2015; 373: 2425-37; https://doi.org/10.1056/NEJMoa1509388
  • Barr PM, Robak T, Owen C, et al. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica 2018; 103: 1502-10; https://doi.org/10.3324/haematol.2018.192328
  • ESMO guidelines committee Chronic lymphocytic leukaemia: eUpdate published online 27 June 2017. Ann Oncol 2017; 28, 149-52; https://doi.org/10.1093/annonc/mdx242
  • Kipps TJ, Stevenson FK, Wu CJ, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Primers 2017; 3: 16096; https://doi.org/10.1038/nrdp.2016.96
  • Wendtner CM, Dreger P, Eichhorst B, et al. Chronische Lymphatische Leukämie (CLL). Onkopedia leitlinien, 2019. Available at https://www.onkopedia.com/de/onkopedia/guidelines/chronische-lymphatische-leukaemie-cll/@@guideline/html/index.html (last accessed October 2019)
  • Medina A, Ramírez A, Hernández J, et al. Guía nacional de leucemia linfática crónica y linfoma linfocítico. Grupo Español de Leucemia Linfocítica Crónica (GELLC), 2019. Available at https://www.sehh.es/images/stories/recursos/2019/06/03/Guia-Clinica-LLC-con-Aval.pdf (last accessed October 2019)
  • Mora A, Bosch R, Cuellar C, et al. CD200 is a useful marker in the diagnosis of chronic lymphocytic leukemia. Cytometry B Clin Cytom 2019; 96: 143-8; https://doi.org/10.1002/cyto.b.21722
  • Parikh SA, Strati P, Tsang M, et al. Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis. Blood 2016; 127: 1752–60; https://doi.org/10.1182/blood-2015-10-620864
  • Condoluci A, Terzi di Bergamo L, Langerbeins P, et al. International Prognostic Score For Early Stage Chronic Lymphocytic Leukemia (IPS A). Hematological Oncology 2019, 37: 81-82; https://doi.org/10.1002/hon.51_2629
  • Baliakas P, Jeromin S, Iskas M, et al.; ERIC, the European Research Initiative on CLL. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood 2019; 133: 1205-16; https://doi.org/10.1182/blood-2018-09-873083
  • Imbruvica – Summary of Product Characteristics
  • Zydelig – Summary of Product Characteristics
  • Venclyxto – Summary of Product Characteristics
  • AIFA – Imbruvica monitoring registry. Available at https://www.aifa.gov.it/it/web/guest/registri-e-piani-terapeutici1 (last accessed October 2019)
  • Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med 2018; 379: 2517-28; https://doi.org/10.1056/NEJMoa1812836
  • Gozzetti A, Candi V, Fabbri A, et al. Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia. Leuk Res 2014; 38: 891-5; https://doi.org/10.1016/j.leukres.2014.05.016
  • Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. N Engl J Med 2019; 381: 432-43; https://doi.org/10.1056/NEJMoa1817073
  • Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood 2016; 127: 208-15; https://doi.org/10.1182/blood-2015-06-651125
  • Eichhorst B, Fink AM, Bahlo J, et al.; international group of investigators; German CLL Study Group (GCLLSG). First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 2016; 17: 928-42; https://doi.org/10.1016/S1470-2045(16)30051-1

Statistics

Abstract: 1205 views
HTML: 599 views
PDF: 450 views

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.